Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Immune system claims require scrutiny
SASP factor levels should begin declining in tissues where clearance was successful
NNMT inhibition addresses this metabolic impairment by enhancing cellular energy metabolism and improving insulin signaling pathways
The authors noted that while oral and topical applications exist, intravenous (IV) deliverylike the vita glow protocolbypasses the digestive system, potentially offering higher bioavailability for systemic effects
Published July 26, 2026 | Written by Optimal Health Medical | Medically reviewed by Dr
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
US$ 26.12
US$ 29.79
US$ 28.41
US$ 29.15
US$ 25.41
US$ 23.95
US$ 25.97
